市場データを読み込み中...
2026年8月7日金曜日
すべての企業
Cigna Group logo

Cigna GroupCI

U.S. LISTEDヘルスケアcigna.com

この企業紹介の日本語訳は準備中です。以下は英語の原文です。

Cigna Groupについて

The Cigna Group is a health services organization built around two principal businesses. Evernorth Health Services, its largest revenue contributor, houses pharmacy benefit management through Express Scripts, specialty pharmacy, care delivery, and benefits administration sold to health plans, employers, and government programs. Cigna Healthcare provides commercial medical insurance and stop-loss coverage, primarily to U.S. employers ranging from small groups to multinational corporations, along with a smaller international health business serving globally mobile employees and expatriates. While Evernorth generates the majority of top-line revenue given the pass-through nature of pharmaceutical dispensing, Cigna Healthcare's commercial insurance book historically contributes a disproportionate share of operating earnings relative to its revenue footprint.

Investors track medical cost ratios in the commercial book, which govern underwriting profitability and can move sharply with utilization trends. Pharmacy benefit economics draw persistent regulatory and political attention, with periodic legislative proposals targeting rebate practices, spread pricing, and vertical integration between PBMs, insurers, and pharmacies. Customer concentration in Evernorth is a durable question, as a handful of large health plan clients represent meaningful share, and contract renewals with those anchors are watched closely. Capital allocation leans on steady buybacks and a dividend, funded by insurance subsidiary upstreaming subject to state regulator approval. Governance features include a unified board following the Express Scripts combination, and the company sits in large-cap managed care index cohorts.

The company traces to Connecticut General Life Insurance, founded in 1865, and INA Corporation, whose Insurance Company of North America dated to 1792. CIGNA was formed by their 1982 merger and progressively pivoted from property-casualty toward health and employee benefits, divesting individual life and P&C lines over subsequent decades. The transformative step came in 2018, when Cigna acquired Express Scripts, then the largest standalone pharmacy benefit manager in the United States, reorganizing the health services businesses under the Evernorth brand in 2020. In 2022 Cigna divested its international life, accident, and supplemental benefits business to Chubb, and in 2024 sold its Medicare Advantage and related businesses to Health Care Service Corporation, sharpening the current two-segment structure.

Revenue reaches Cigna through several channels with distinct economics. Employers, unions, and government payers contract with Express Scripts for pharmacy benefit administration, with fees, rebate retention, and pharmacy network spread forming the earnings mix; specialty pharmacy dispensing of high-cost drugs is a significant component. In Cigna Healthcare, self-funded employer clients pay administrative service fees while Cigna bears clinical management and, under stop-loss, tail claims risk; fully insured commercial and international customers pay premiums against which medical claims are underwritten. Competitive position rests on scale in pharmacy purchasing, integrated clinical programs, and national provider networks, positioning it against UnitedHealth, CVS Health, Elevance, and Humana. Revenue is overwhelmingly domestic.

企業プロフィールはLineVest編集部によるものです。ジャーナリズムであり、投資助言ではありません。 Cigna GroupのSECベース詳細レポートを依頼 →

Cigna Group関連記事

Cigna Groupの記事はまだありません — LineVestは米国市場ニュースを毎日発行しており、Cigna Groupの新しい記事は自動的にここに表示されます。

最新の米国市場ニュースを見る →

見出しの先を読む

何が起きたかは読みました。次は、それが何を意味するかを。

無料デイリーブリーフィング

米国市場を毎朝 — 無料で

LineVest Dailyが寄付き前に届きます:米国市場の主要ストーリー、決算、開示、外国人フロー — わかりやすい英語で。無料、カード登録不要。

LineVest Dailyを無料で →
この企業

Cigna Groupの詳細レポート

Cigna Groupの最新SEC開示を全て読み込みます — US GAAPの財務、ガバナンス、株価への意味まで。3時間以内にPDFでお届け。

$12・買い切り

Cigna Groupレポートを入手
ウォッチ銘柄すべて

市場全体をフォロー

週に何銘柄も米国株を見ていますか?すべての分析記事を公開と同時に — デイリーの米国市場全カバレッジと90日アーカイブ。

$9.99・月額

購読する

一次資料のSEC開示に基づく独立ジャーナリズム — 投資助言ではありません。証券会社との提携はありません。